Breast cancer is the most common type of cancer in women. Although most cases of early-stage non-metastatic disease are curable with surgery, effective treatments for later-stage and metastatic disease remain an unmet need. Several immunotherapies have received FDA approval for the treatment of breast cancer, including pembrolizumab, atezolizumab and trastuzumab deruxtecan.
In this podcast, Rebecca Dent, MD, FRCP, of the National Cancer Centre Singapore, Rupert Bartsch, MD, of the Medical University of Vienna in Austria, and Marleen Kok, MD, PhD, of the Netherlands Cancer Institute in Amsterdam, discuss key updates on immunotherapies for the treatment of breast cancer, as presented at the 2021 ESMO Breast Cancer Virtual Meeting.
